Eli Lilly & CO Schedule 13G passive stakes

Eli Lilly and Company has reported a significant beneficial ownership stake of 15.6% in ProQR Therapeutics N.V., holding 21,995,880 ordinary shares.

Eli Lilly and Company has reported beneficial ownership of 7.9% of Ionetix Corp's common stock as of April 9, 2026.

Lilly Endowment, Inc. has disclosed a beneficial ownership of 90,376,978 shares of Eli Lilly and Company common stock, representing 9.6% of the outstanding shares as of June 30, 2026.

Lilly Endowment, Inc. has disclosed a beneficial ownership of 91,896,978 shares, representing 9.7% of Eli Lilly and Company's common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G for Eli Lilly & Co, reporting 0% beneficial ownership following an internal corporate realignment.

Lilly Endowment, Inc. filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.8% of Eli Lilly and Company's common stock as of December 31, 2025.

Lilly Endowment, Inc. reported a 10.1% beneficial ownership stake in Eli Lilly and Company as of September 30, 2025, holding 95,492,993 shares.

The Vanguard Group has filed an amendment to its Schedule 13G, disclosing an 8.55% beneficial ownership in Eli Lilly & Co as of September 30, 2025.

Eli Lilly and its subsidiary, Eli Lilly S.A., have reported zero beneficial ownership in Immunocore Holdings plc, indicating a complete divestment of their previous stake.

Lilly Endowment Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 10.1% of Eli Lilly and Co.'s common stock as of March 31, 2025.

The PNC Financial Services Group, Inc. has disclosed a beneficial ownership of 5.39% of Eli Lilly and Company's common stock, primarily through its role as a directed trustee for the Eli Lilly and Company Compensation Trust.

Lilly Endowment Inc. has filed an amendment to its Schedule 13G, reaffirming its beneficial ownership of 10.2% of Eli Lilly and Co.'s common stock as of December 31, 2024.